Dyslipidemia Drugs Market is Estimated to Reach a USD 6.9 billion in 202314 Dec 2015
Dyslipidemia is a chronic metabolic syndrome, characterized by improper level of low density lipoprotein, high density lipoprotein, and triglycerides. This study on the dyslipidemia drugs market involves the analysis of a wide range of therapeutics that help patients to treat lipid disorders. The dyslipidemia drugs market promises lucrative growth opportunities for pharmaceutical manufacturers due to increasing demand and prescriptions of these medications. According to the Centers for Disease Control and Prevention, cholesterol abnormalities are rapidly increasing in developed regions such as North America and Europe. Moreover, several articles published in open journals stated that demand for lipid lowering drugs is increasing in countries such as China, India, and Japan. However, loss of patent exclusivity of molecules such as Crestor, Zetia, and Vytorin is expected to hamper the growth of the market during the forecast period.
Request Of A Sample Report:- http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1535
This report comprises a detailed study of various drug classes for the treatment of dyslipidemia. The dyslipidemia drugs market has been segmented into statins, bile acid resins, fibric acid derivatives, niacins, and others (combination drugs and cholesterol absorption inhibitors). The statins segment comprises combined market revenue of statin drugs such as atorvastatin, fluvastatin, rosuvastatin, pravastatin, simvastatin, pitavastatin, and lovastatin. The bile acid resins segment included resins such as Cholestyramine, Colestipol, Colesevelam, and Cholybar. The fibric acid, and omega-3 fatty acid derivatives segment comprises generic drugs such as Fenofibrate, Clofibrate, and Bezafibrate. Other branded omega-3 fatty acids include Lovaza, Vascespa, and Omtryg. Niacins includes drugs such as Niaspan, Slo-Niacin, and Niacor. The others segment encompasses market analysis of combination drug therapies such as Advicor, Vytorin, and Caduet, as well as cholesterol inhibitor drugs. The market size and forecast for each drug class has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (% CAGR) for the forecast period from 2015 to 2023 for each drug class, considering 2013 to 2014 as the historical and base year, respectively.
By geography, the dyslipidemia drugs market has been studied for five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Each region has been further divided into major countries i.e., North America: the U.S. and Canada; Europe: Germany, France, the U.K. and Rest of Europe; Asia Pacific: China, Japan, India and Rest of APAC; Latin America: Brazil and Rest of LATAM; Middle East and Africa: South Africa and Rest of MEA. The market size and forecast for each region and country has been estimated for the period 2013 to 2023 in terms of revenue (USD million). The report also provides the compound annual growth rate (CAGR %) during the forecast period from 2015 to 2023 for all the regions and countries mentioned above.
The market overview section of the report discusses the market dynamics with respect to the market drivers, restraints, and opportunities. This section also covers information on epidemiology, etiology, dyslipidemia diagnostics, trends and future aspects, and market attractiveness analysis, by geography of the dyslipidemia drugs market. A list of recommendations for existing and new players to enter the market and enhance their position is also provided in the report. The report concludes with company profiles of key players operating in various drug classes of the market. Each company profile includes business overview, financial overview, product portfolio, business strategies, and recent developments of the respective market player. Prominent players in the dyslipidemia drugs market that have been profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Mylan N.V., Merck & Co., Inc., and AstraZeneca plc
The global dyslipidemia drugs market is segmented as follows:
Global Dyslipidemia Drugs Market, by Drug Class
- Bile Acid Resins
- Fibric Acid and Omega-3 Fatty Acid Derivatives
- Others (Combination Drugs and Cholesterol Absorption Inhibitors)
Global Dyslipidemia Drugs Market, by Geography
- North America
- Latin America
- Middle East and Africa (MEA)
Browse Full Report With TOC:- http://www.transparencymarketresearch.com/dyslipidemia-market.html
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Transparency Market Research
90 State Street,
Albany NY - 12207